Previous studies have demonstrated that the expression level of UCHL5 and associated clinical outcome vary among cancers including gastric, rectal, pancreas, esophageal, hepatocellular, and ovarian cancer [32–37]. This evidence concerns the gene UCHL5 and ovarian carcinoma.